life scienc tool diagnost increas target price
beat estim better revenu profit factor line
ad importantli unveil initi guidanc call revenu increas
million midpoint essenti par estimate consensu
adjust ebitda million midpoint slightli ahead street
million impli essenti flat ebitda margin y/i albeit well plan bp
rais non-gaap ep estimate reflect better revenu
growth profit experi tp move higher view
greater convict growth prospect strong fundament backdrop
revenu profit prevail net btb vs estimate total revenu jump
well plan post lighter net book-to-bil
estimate backlog convers vs estimate rose bp
sequenti end backlog expand billion net new busi
industri average backlog burn rel lower book-to-bil ebitda margin contract
bp bp better plan continu step invest
support growth flow million cash reserv stand
million net dso declin day
reiter outperform despit recent ralli ytd vs flat momentum
share may continu latest oper guidanc upsid
importantli initi target allud continu double-digit revenu growth
midpoint ahead industri sustain ebitda margin higher-
end cro peer averag await greater call clariti bookings/cancel
dynam quarterli profit cadenc hire assumpt new larg
custom relationship greater larg pharma disclos well latest industri
demand trend particularli across core biotech custom base revenu
explicit non-gaap ep guidanc metric provid previou disclosur
valuat metric
number share
 close
legal entiti disclosur statu non-u analyst us disclosur credit suiss seek busi
compani cover research report result investor awar firm may conflict interest could
affect object report investor consid report singl factor make invest decis
medpac full-servic therapeutically-focus contract research
organ cro cover phase i-iv develop servic
biopharmaceut medic devic industri
blue sky valuat assum signific
acceler organ sale growth healthi fund environ
increas profit success new servic offer substanti new
busi win continu strong outsourc demand small/mid-
grey sky valuat assum deceler
sale growth declin profit weaken demand
small/mid-s biotech custom custom consolid
slowdown overal spend
 close
profit tax
chang work capit
oper
flow oper
free cash-flow firm
flow invest
cash-flow financ activ
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
price
result better expect oper perspect howev quarterli
net book-to-bil slightli assumpt deceler rel
btb previou quarter still net new busi step million
y/i backlog convers improv sequenti basi vs
focu tuesday confer call like profit dynam non-
gaap ep guidanc natur recent new busi win pass-through dynam well
underli health industri fundament particularli across core custom
base smid biopharma repres revenu
context one conserv book polici across public cro
univers includ maximum three year expect revenu given project
backlog recogn project backlog begun gener revenu
key contribut factor industry-lead backlog convers rate lower book-to-bil
rel peer thu emphas import look two metric
backlog convers book-to-bil simultan
compani data credit suiss estim factset industri averag includ iclr
guidanc detail basi provid initi guidanc call
revenu million midpoint await greater detail
cancellation/book assumpt importantli adjust ebitda guidanc
million impli sustain ebitda margin expans midpoint ahead
consensu expect disconnect prior disclosur provid
ep detail may compar call ep still
estim consensu
book-to-billindustri book-to-billnot compar due vs prior charl martineau pm univers toronto
compani data credit suiss estim factset industri averag includ iclr
custom mix updat note follow metric report basi small
biopharmaceut compani repres revenu ytd vs
underscor greater exposur faster-grow albeit volatil custom segment
exposur smaller sometim pre-revenu sponsor compani help contribut
rel divers custom base top five custom repres revenu
vs medp custom base concentr rel stabl overal
previou quarter disclosur top contribut revenu ytd vs
contribut larg pharma revenu ytd vs
therapeut categori maintain higher exposur complex area oncolog
ytd revenu avai antiviral/infecti diseas repres revenu
continu grow therapeut area note avai trial tend larger size
shorter durat estimate year compar oncolog trial estimate year
edp quarterli dso decreas day vs day previou quarter
flow million cash reserv stand million
thesi remain continu benefit strong cro fundament
backdrop leverag disciplin science-driven full-servic approach uniqu
model offer competit advantag grow ahead industri longer
term sustain profit without meaning capit requir support double-digit
revenu ep growth longer term follow transit period recent cancel
invest initi
confer call detail manag host confer call discuss result
tuesday morn et dial passcod
conversionttm backlog conversionindustri backlog convers compar due vs prior charl martineau pm univers toronto februari
compani data credit suiss estim factset million except per share note net
incom guidanc metric
forecast revenu grow million driven increas
net new busi new project new exist client expect ebitda margin
expand bp despit acceler invest increas headcount ep
increas
ep share trade premium peer group relev
contract research organ target price base price-to-earnings multipl
view repres compani top-line growth trajectori
compani mention price
erin wilson wright certifi view express report accur reflect person view subject compani
secur part compens directli indirectli relat specif recommend view
express report
price rate histori icon plc iclr oq
signifi initi assumpt coverag
price rate histori inc iqv
signifi initi assumpt coverag
price rate histori inc medp oq
signifi initi assumpt coverag
price rate histori inc oq
signifi initi assumpt coverag
price rate histori syneo health synh oq
signifi initi assumpt coverag
decemb analyst stock rate defin follow
outperform stock total return expect outperform relev benchmark next month
neutral stock total return expect line relev benchmark next month
under-perform stock total return expect under-perform relev benchmark next month
relev benchmark region decemb japanes rate base stock total return rel analyst coverag univers
consist compani cover analyst within relev sector outperform repres attract neutral less attract
underperform least attract invest opportun octob canadian well europea exclud turkey rate
base stock total return rel analyst coverag univers consist compani cover alyst within relev sector
outperform repres attract neutral less attract underperform least attract invest opportun latin america
turkey asia exclud japan australia stock rate base stock total return rel averag tal return relev countri
region benchmark india bse sensex index prior octob canadian rate base stock absolut total return
potenti current share price rel attract stock total return potenti withi analyst coverag univers australian
new zealand stock expect total return calcul includ roll dividend yield outperform rate assign
greater equal under-perform less equal neutral may assign
overlap rate rang allow analyst assign rate put context associ risk prior may rang outperform
under-perform rate overlap neutral threshold oper juli
restrict certain circumst credit suiss polici and/or applic law regul preclud certain type commun
includ invest recommend cours credit suiss engag invest bank transact certain
circumst
rate nr credit suiss equiti research invest rate view stock secur relat
compani time
cover nc credit suiss equiti research provid on-going coverag compani offer invest rate
invest view equiti secur compani relat product
volatil indic stock defin volatil stock price move month least
past month analyst expect signific volatil go forward
analyst sector weight distinct analyst stock rate base analyst expect fundament and/or
valuat sector rel group histor fundament and/or valuat
overweight analyst expect sector fundament and/or valuat favor next month
market weight analyst expect sector fundament and/or valuat neutral next month
underweight analyst expect sector fundament and/or valuat cautiou next month
analyst coverag sector consist compani cover analyst within relev sector analyst may cov er multipl sector
credit suiss distribut stock rate bank client
bank client
purpos nyse finra rate distribut disclosur requir stock rate outperform neutral nd under-perform close
